Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cariprazine in pediatric ASD
NCT05439616Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2022
- Primary completion
- Oct 2024
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of cariprazine in Autism Spectrum Disorder (ASD), sponsored by AbbVie Inc.. Started Jul 2022; status: completed.
02
Drugs
cariprazine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT05439616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05439616.